search
Back to results

Effect of Transcutaneous Auricular Vagus Nerve Stimulation on Gait Characteristics in Parkinson's Disease

Primary Purpose

Parkinson Disease, Gait Disorders, Neurologic

Status
Completed
Phase
Not Applicable
Locations
Slovenia
Study Type
Interventional
Intervention
Noninvasive transcutaneous auricular vagus nerve stimulation at 100Hz
Noninvasive transcutaneous auricular vagus nerve stimulation at 25Hz
Noninvasive transcutaneous earlobe stimulation at 25Hz
Sponsored by
University Medical Centre Ljubljana
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Parkinson Disease focused on measuring parkinson's disease, taVNS, motion sensors

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: HYstage >2 L-dopa unresponsive gait characteristics present, preferably with history of freezings Exclusion Criteria: unable to walk for 50m unable to follow simple commands due to hearing loss/cognitive impairment

Sites / Locations

  • Neurology Department, UMC Ljubljana

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

No Intervention

Active Comparator

Active Comparator

Sham Comparator

Arm Label

baseline

taVNS100

taVNS25

sVNS

Arm Description

Participants will receive no stimulation, the electrode will be placed in the ear in a random position and turned off. Participants will complete 4 instrumented stand and walk tests - 2 without performing calculations and 2 with performing calculations aloud.

Noninvasive electrostimulation will be applied to the left cyma conchae through the Nemos® electrode at 100Hz. Participants will complete 4 instrumented stand and walk tests - 2 without performing calculations and 2 with performing calculations aloud.

Noninvasive electrostimulation will be applied to the left cyma conchae through the Nemos® electrode at 25Hz. Participants will complete 4 instrumented stand and walk tests - 2 without performing calculations and 2 with performing calculations aloud.

Noninvasive electrostimulation will be applied to the left earlobe through the Nemos® electrode at 25Hz. Participants will complete 4 instrumented stand and walk tests - 2 without performing calculations and 2 with performing calculations aloud.

Outcomes

Primary Outcome Measures

Arm Swing Velocity
The average velocity of upper extremities in degrees per second as produced by the Mobility Lab software.
Arm Range of Motion
The average wrist range of motion in degrees as produced by the Mobility Lab software.
Stride Length
The average stride length in m as produced by the Mobility Lab software.
Gait Speed
The average speed of gait in m/s as produced by the Mobility Lab software.
Arm Range of Motion Asymmetry
The average difference between left and right arm range of motion in degrees as produced by the Mobility Lab software.
Anticipatory Postural Adjustment (APA) duration
The average duration of anticipatory postural adjustments in seconds as produced by the Mobility Lab software.
APA First step Duration
The average duration of the first detected step in seconds as produced by the Mobility Lab software.
APA First Step range of motion
The average range of motion of the first detected step as produced by the Mobility Lab software.

Secondary Outcome Measures

Full Information

First Posted
December 19, 2022
Last Updated
October 16, 2023
Sponsor
University Medical Centre Ljubljana
search

1. Study Identification

Unique Protocol Identification Number
NCT05683925
Brief Title
Effect of Transcutaneous Auricular Vagus Nerve Stimulation on Gait Characteristics in Parkinson's Disease
Official Title
Effect of Transcutaneous Auricular Vagus Nerve Stimulation at 25Hz and 100Hz on Levodopa Responsive and Non-responsive Gait Characteristics in Parkinson's Disease- a Motion Sensor Study
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Completed
Study Start Date
September 1, 2022 (Actual)
Primary Completion Date
February 15, 2023 (Actual)
Study Completion Date
February 15, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University Medical Centre Ljubljana

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
In this randomised placebo-controlled trial, the investigators will include 30 PD (Parkinson's disease) patients with HY (Hoehn Yahr stage) >2 and L-dopa unresponsive gait characteristics. Each participant will receive taVNS at 25Hz, taVNS at 100Hz and sham VNS (sVNS). During each stimulation, different gait characteristics will be measured with wearable insertion motion sensors.
Detailed Description
Participants and study overview: In this randomised placebo-controlled trial, the investigators will include 30 PD patients with HY>2 and L-dopa unresponsive gait characteristics. Each participant will complete 1 visit, during which the instrumented stand and walk test will be repeated 16 times. The baseline measurement will be followed by three different stimulation conditions sham VNS (sVNS), taVNS at 25Hz (taVNS25) and taVNS a 100Hz (taVNS100). sVNS, taVNS25 and taVNS100 in a randomized order. To enhance gait disturbances, the participants will perform iSAW during each condition twice in silence and twice while simultaneously performing calculations around. Instrumented stand and walk test (iSAW): To perform iSAW, participants will first stand still for 30s, after which they will start walking in a straight line for 7m, turn and walk back to the start. The participants will be equipped with 6 inertion Opal ® motion sensors (on both feet, both wrists, on the lumbar back and on their sternum). For the laud counting iSAW condition (iSAW-C), the participants will perform iSAW as described above while also counting backwards by 3 from numbers above 100. TaVNS: Noninvasive electrostimulation will be applied to the left ear. taVNS will be applied to the cyma conchae and sVNS will be applied to the earlobe. Both taVNS and sVNS were applied through the Nemos® electrode with the following parameters: square-shaped pseudobiphasic pulse, interpulse duration 80μs, pulse width 300μs, pulse intensity 0,1mA above the perceptual threshold (figure 1). taVNS25 and sVNS will be applied at 25Hz and taVNS100 will be applied at 100Hz. The intensity for each separate stimulation will be adjusted for each participant at the beginning of the experiment. For each condition, the electrode will be placed in the ear by a third person and the ear will be covered by cotton pads and an EEG cap to hide the electrode position from the experimenter. The order of stimulation will not be revealed until the automated data and statistical analysis.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Parkinson Disease, Gait Disorders, Neurologic
Keywords
parkinson's disease, taVNS, motion sensors

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Model Description
Participants and study overview In this randomised placebo controlled trial, the investigators will include 30 PD patients with HY>2 and L-dopa unresponsive gait characteristics. Each participant will complete 1 visit, during which the instrumented stand and walk test will be repeated 16 times. The baseline measurement will be followed by three different stimulation conditions sham VNS (sVNS), taVNS at 25Hz (taVNS25) and taVNS a 100Hz (taVNS100). sVNS, taVNS25 and taVNS100 in a randomized order. To enhance gait disturbances, the participants will preform iSAW during each condition twice in silence and twice while simultaneously performing calculations around.
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
Noninvasive electrostimulation will be applied to the left ear. taVNS will be applied to the cyma conchae and sVNS will be applied to the earlobe - participants will not be told which is the active and which is the sham condition. Both taVNS and sVNS were applied through the Nemos® electrode. The intensity for each separate stimulation will be adjusted for each participant at the beginning of the experiment. For each condition, the electrode will be placed in the ear by a third person and the ear will be covered by cotton pads and an EEG cap to hide the electrode position from the experimenter. The order of stimulation will not be revealed until the automated data and statistical analysis.
Allocation
Randomized
Enrollment
30 (Actual)

8. Arms, Groups, and Interventions

Arm Title
baseline
Arm Type
No Intervention
Arm Description
Participants will receive no stimulation, the electrode will be placed in the ear in a random position and turned off. Participants will complete 4 instrumented stand and walk tests - 2 without performing calculations and 2 with performing calculations aloud.
Arm Title
taVNS100
Arm Type
Active Comparator
Arm Description
Noninvasive electrostimulation will be applied to the left cyma conchae through the Nemos® electrode at 100Hz. Participants will complete 4 instrumented stand and walk tests - 2 without performing calculations and 2 with performing calculations aloud.
Arm Title
taVNS25
Arm Type
Active Comparator
Arm Description
Noninvasive electrostimulation will be applied to the left cyma conchae through the Nemos® electrode at 25Hz. Participants will complete 4 instrumented stand and walk tests - 2 without performing calculations and 2 with performing calculations aloud.
Arm Title
sVNS
Arm Type
Sham Comparator
Arm Description
Noninvasive electrostimulation will be applied to the left earlobe through the Nemos® electrode at 25Hz. Participants will complete 4 instrumented stand and walk tests - 2 without performing calculations and 2 with performing calculations aloud.
Intervention Type
Device
Intervention Name(s)
Noninvasive transcutaneous auricular vagus nerve stimulation at 100Hz
Other Intervention Name(s)
taVNS100
Intervention Description
Noninvasive electrostimulation will be applied to the left cyma conchae through the Nemos® electrode with the following parameters: square-shaped pseudobiphasic pulse, interpulse duration 80μs, pulse width 300μs, pulse intensity 0,1mA above the perceptual threshold at 100Hz. The intensity for each separate stimulation will be adjusted for each participant at the beginning of the experiment.
Intervention Type
Device
Intervention Name(s)
Noninvasive transcutaneous auricular vagus nerve stimulation at 25Hz
Other Intervention Name(s)
taVNS25
Intervention Description
Noninvasive electrostimulation will be applied to the left cyma conchae through the Nemos® electrode with the following parameters: square-shaped pseudobiphasic pulse, interpulse duration 80μs, pulse width 300μs, pulse intensity 0,1mA above the perceptual threshold at 25Hz. The intensity for each separate stimulation will be adjusted for each participant at the beginning of the experiment.
Intervention Type
Device
Intervention Name(s)
Noninvasive transcutaneous earlobe stimulation at 25Hz
Other Intervention Name(s)
sVNS
Intervention Description
Noninvasive electrostimulation will be applied to the left earlobe through the Nemos® electrode with the following parameters: square-shaped pseudobiphasic pulse, interpulse duration 80μs, pulse width 300μs, pulse intensity 0,1mA above the perceptual threshold at 25Hz. The intensity for each separate stimulation will be adjusted for each participant at the beginning of the experiment.
Primary Outcome Measure Information:
Title
Arm Swing Velocity
Description
The average velocity of upper extremities in degrees per second as produced by the Mobility Lab software.
Time Frame
This will be measured acutely, e. i. during taVNS/sVNS and compared to baseline measurements.
Title
Arm Range of Motion
Description
The average wrist range of motion in degrees as produced by the Mobility Lab software.
Time Frame
This will be measured acutely, e. i. during taVNS/sVNS and compared to baseline measurements.
Title
Stride Length
Description
The average stride length in m as produced by the Mobility Lab software.
Time Frame
This will be measured acutely, e. i. during taVNS/sVNS and compared to baseline measurements.
Title
Gait Speed
Description
The average speed of gait in m/s as produced by the Mobility Lab software.
Time Frame
This will be measured acutely, e. i. during taVNS/sVNS and compared to baseline measurements.
Title
Arm Range of Motion Asymmetry
Description
The average difference between left and right arm range of motion in degrees as produced by the Mobility Lab software.
Time Frame
This will be measured acutely, e. i. during taVNS/sVNS and compared to baseline measurements.
Title
Anticipatory Postural Adjustment (APA) duration
Description
The average duration of anticipatory postural adjustments in seconds as produced by the Mobility Lab software.
Time Frame
This will be measured acutely, e. i. during taVNS/sVNS and compared to baseline measurements.
Title
APA First step Duration
Description
The average duration of the first detected step in seconds as produced by the Mobility Lab software.
Time Frame
This will be measured acutely, e. i. during taVNS/sVNS and compared to baseline measurements.
Title
APA First Step range of motion
Description
The average range of motion of the first detected step as produced by the Mobility Lab software.
Time Frame
This will be measured acutely, e. i. during taVNS/sVNS and compared to baseline measurements.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: HYstage >2 L-dopa unresponsive gait characteristics present, preferably with history of freezings Exclusion Criteria: unable to walk for 50m unable to follow simple commands due to hearing loss/cognitive impairment
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Maja Kojović, MD, PhD
Organizational Affiliation
University Medical Centre Ljubljana
Official's Role
Principal Investigator
Facility Information:
Facility Name
Neurology Department, UMC Ljubljana
City
Ljubljana
ZIP/Postal Code
1000
Country
Slovenia

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
The investigators plan to share the anonymised data with researchers upon request.
IPD Sharing Time Frame
Upon request after study publication.
IPD Sharing Access Criteria
Data will be shared with researchers upon reasonable request.

Learn more about this trial

Effect of Transcutaneous Auricular Vagus Nerve Stimulation on Gait Characteristics in Parkinson's Disease

We'll reach out to this number within 24 hrs